Dr. Gerds on Future Treatment of Patients With Myeloproliferative Neoplasms

Aaron Gerds, MD
Published: Tuesday, Jan 14, 2020



Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms (MPNs) through the use of JAK-STAT pathway.

The JAK inhibitors, fedratinib (Inrebic) and ruxolitinib (Jakafi), have recently been approved by the FDA for the treatment of patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera) myelofibrosis. Hydroxyurea has been a common therapy for patients with myelofibrosis and PV. For patients who have not responded to hydroxyurea, fedratinib and ruxolitinib offer a second-line therapy option.

The availability of fedratinib and ruxolitinib in the MPN treatment landscape will serve as the backbone of future research, Gerds concludes.
SELECTED
LANGUAGE


Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms (MPNs) through the use of JAK-STAT pathway.

The JAK inhibitors, fedratinib (Inrebic) and ruxolitinib (Jakafi), have recently been approved by the FDA for the treatment of patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera) myelofibrosis. Hydroxyurea has been a common therapy for patients with myelofibrosis and PV. For patients who have not responded to hydroxyurea, fedratinib and ruxolitinib offer a second-line therapy option.

The availability of fedratinib and ruxolitinib in the MPN treatment landscape will serve as the backbone of future research, Gerds concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x